Trial intelligence / Profile preview

Pre-DM: Strategies to Prevent Prediabetes Progression in Hispanics

NCT06446531Phase 1Recruiting

Sponsor: UT Health San Antonio
Start: Sep 2024
Primary completion: Jul 2027
Modality: Peptides, Recombinant Proteins and Enzymes, Small Molecules
Countries: 1

Overview

Phase 1, randomised, single-blind trial of empagliflozin, semaglutide, liquid metformin (Aspargo Labs) and pioglitazone in prediabetes, obesity and cardiovascular diseases (CVD) (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Hemoglobin A1c at 6 months. Started Sep 2024; status: recruiting.

Drugs

empagliflozinsemaglutideliquid metformin (Aspargo Labs)pioglitazone

Conditions

prediabetesobesitycardiovascular diseases (CVD)

Beyond the preview

Go deeper on NCT06446531.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06446531.